Skip to main content
OpenTrials
Completed

NCT Number: NCT00889538

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

This is a double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of glutathione alone or glutathione, vitamin C and NAC treatment in children with autism who also have severe behavior problems. The investigators hypothesis is that children with autism will show improvement in both learning capabilities and behavior with either glutathione, or glutathione, vitamin C and NAC therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KCPCRU

Louisville, Kentucky, 40202, United States

About this study

This is a prospective, single center, double-blind, randomized pilot study in children and adolescents with autism and severe behavior disorders. All subjects will undergo initial screening procedures to determine eligibility. They will then be randomized to either 8 weeks of placebo or 8 weeks of glutathione or glutathione, vitamin C and N-acetylcysteine. They will receive intravenous treatment weekly and will have ongoing behavioral studies during this period. Following 8 weeks of therapy, they will have a week without treatment then will cross-over to the alternate therapy for weekly intravenous infusions and behavioral testing. In addition to baseline hematology and chemistries, baseline oxidized and reduced glutathione will be measured. These parameters will be repeated at the end of each 8 week course of therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 5 to 16 years, inclusive
  • Diagnosed with autism using the ADI-R (Autism Diagnostic Interview-Revised)
  • ABC Irritability/Agitation subscale score (Aberrant Behavior Checklist Subscale) ≥ 18
  • CGI-S score (Clinical Global Impression-Severity Scale) ≥ 4
  • Must be drug naïve or on a stable dose of medication(s) and educational/behavioral interventions for one month prior to participation
  • Parent/legal guardian must provide written consent and required research authorization (i.e. HIPAA) prior to the performance of any study procedures.

Exclusion criteria

  • Presence of another disorder on the autism spectrum including PDD-NOS (Pervasive Developmental Disorder Not Otherwise Specified), Asperger's, and Rett's Syndrome
  • Patient with a known cause of autism such as Fragile X
  • Evidence of significant renal dysfunction (e.g. GFR estimated by the Schwartz formula < 50 mL/min or serum creatinine > 2.5 X upper limit of normal for age)
  • Evidence of significant hepatic dysfunction (serum transaminases > 2.5 X the upper limit of normal)
  • Known hypersensitivity to glutathione, vitamin C or NAC
  • Pregnant or lactating female
  • Inability of subject and parent to be able to comply with requirements for study visits and procedures
  • Presence of major mental illness
  • History of antioxidant supplementation.

Treatment and study plan

Placebo

Drug

50 mL of 1/2 normal saline IV

Glutathione

Drug

glutathione 600 mg IV

glutathione, vit C and NAC

Drug

Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL

Other names: NAC

Primary outcomes

  1. Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.

    Time frame: 4 months

    Improvement in both developmental skills and behavior measured using validated scales in subjects receiving either glutathione, glutathione/Vitamin C/N-acetylcysteine or placebo measured at baseline, 9 weeks and at the end of study in a double-blind cross-over design.

Secondary outcomes

  1. Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio

    Time frame: Baseline

  2. Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio

    Time frame: 9 weeks

  3. Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio

    Time frame: 18 weeks

Sponsors and collaborators

Lead sponsor

University of Louisville

Other

Collaborators

  • Cumberland Pharmaceuticals
  • Norton Healthcare

Registry information

Official study title

Double-Blind, Placebo-Controlled, Crossover Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Apr 29, 2009
Registry last updated
Dec 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.